Immunity to "reinfection malaria" or "premunition" was studied in B-celldeficient mice which had previously experienced acute malaria caused by the avirulent plasmodia Plasmodium yoelii or P. chabaudi or by the lethal P. vinckei. Such mice resisted challenge infection with large numbers of homologous parasites but differed in their capacity to resist challenge with heterologous species. Mice immune to P. yoelii resisted infection with P. chabaudi but developed acute-type, albeit nonlethal, infections when challenged with P. vinckei. Whereas mice immune to P. chabaudi resisted challenge with P. vinckei and vice versa, they developed fulminating malaria and died when infected with P. yoelii. The data suggest that immunity to reinfection malaria in B-cell-deficient mice, although antibody independent, is mediated by different mechanisms of resistance depending upon the plasmodial species used to initiate acute infection. Additional evidence supporting this concept was gained from preliminary experiments in which immunity to reinfection was measured by the ability of chronically infected mice to control endogenous parasites at low levels. B-cell-deficient mouse strains showed genotypic differences in their ability to develop immunity to reinfection with P. yoelii. In contrast, the same mouse strains uniformly developed immunity to reinfection with P. chabaudi. These findings suggest that different genetic loci control resistance to reinfection malaria caused by different species of plasmodia. Finally, B-cell-deficient mice acutely infected with lethal plasmodia, P. vinckei or P. berghei, died at the same time or earlier than similarly infected immunologically intact mice, indicating that "early death" in virulent malarial infections is an antibody-independent phenomenon.
Resistance to malaria is a complex phenomenon involving both innate and acquired immune responses (6, 14) . Whereas the mechanisms involved in the resolution of acute infections or control of chronic disease or both remain to be determined, T cells are likely to be involved (2) .
Whether they function as helper cells in the production of protective antibodies or manifest their protective activity by some other means remains controversial.
Studies in our laboratory have utilized immunodeficient animals to investigate the role of Tand B-lymphocyte systems in resisting experimental malaria. Thus, acute Plaspnodium gallinaceum infections of chickens (16) and acute P. yoelii infections of mice (17) were lethal if their respective hosts lacked either T or B cells. Similar findings have been reported previously by others (4, 22, 26) . However, when these otherwise lethal infections were controlled in Bcell-deficient animals by short-term chemotherapy, the animals subsequently developed chronic low-grade malaria and resisted challenge infection with homologous parasites (10, 16, 19) . These data suggested that, whereas acute malarial infections caused by these species of plasmodia were controlled by antibody-dependent mechanisms of immunity, resistance to "reinfection malaria" in B-cell-deficient hosts was mediated by antibody-independent mechanisms of immunity. After the termination of drug therapy, acute-type malaria did recur in both athymic nude mice (17) and thymectomized-irradiated chickens (Grun and Weidanz, unpublished data), indicating that immunity to reinfection malaria in chronically infected B-cell-deficient hosts was thymus dependent. Subsequent studies with yet another murine plasmodial species, P. chabaudi, demonstrated that acute infections initiated with this parasite, in contrast to the above, were terminated spontaneously by antibody-independent mechanisms of immunity which were T-cell dependent (12) . After the resolution of their acute infections, B-1198 GRUN AND WEIDANZ cell-deficient mice developed chronic P. chabaudi malaria and resisted challenge infection with homologous parasites.
These findings showed that immunity to acute malaria caused by different plasmodial species could be differentiated from the need for B-celldependent mechanisms to participate in the termination of acute infection; i.e., acute P. yoelii infections required B-cell participation, whereas acute P. chabaudi malaria was controlled by Bcell-independent mechanisms of immunity. Chronic malaria in B-cell-deficient mice regardless of etiology was controlled by antibodyindependent mechanisms of immunity.
We now describe studies characterizing more fully acute malarial infections in B-cell-deficient mice caused by different species of plasmodia, as well as selected parameters of immunity induced in B-cell-deficient mice which had been immunized by acute infection. In addition, we have examined immunity to reinfection malaria or "premunition" (20) in B-cell-deficient mice which had previously experienced acute malaria resulting from infection with different species of murine plasmodia. To accomplish this, we have utilized two parameters of immunity to measure resistance in the immunized host: (i) the ability of the chronically infected B-cell-deficient mouse to control endogenous parasites at low levels, and (ii) the ability of B-cell-deficient mice which had previously experienced acute malaria to resist challenge with homologous as well as heterologous plasmodia. Data to be presented suggest that immunity to reinfection malaria, although antibody independent, may be mediated by different mechanisms of immunity depending upon the plasmodial species used to initiate acute infection.
MATERIALS AND METHODS
Mice. Male and female mice of the following strains were bred and housed under optimal conditions in our closed colony: C57BL/10, BALB/c, (BALB/c x C57BL/10)Fl, and (C57BL/10 x BALB/c)F1. These animals were derived from C57BL/10 breeding pairs kindly supplied by Carole Long, Hahnemann University, and BALB/c parental stock originally purchased from the Institute for Cancer Research, Fox Chase, Pa.
In vivo suppression of B-cell development with anti-Ft.
Selected litters of mice were rendered B-cell deficient by a modification of methods described previously (17) . Briefly, antiserum prepared in goats (anti-p.) against a purified mouse myeloma protein, MOPC 104E (p.,X; Litton Bionetics), was heat inactivated, adsorbed with 5% washed mouse erythrocytes, sterilized by filtration, and stored at -20°C until used. Newborn mice were given daily injections of hightitered anti-p. for the first 2 or 3 days of life; thereafter, they were maintained on thrice-weekly injections for the duration of the experiments. Compared with immunologically intact animals, mice treated with anti-,u in this manner demonstrated severe B-cell deficiencies, but normal T-cell responsiveness (12) . Although not an absolute indicator of the B-cell deficiency achieved by repeated treatment with anti-p., good correlation was found between the B-cell-deficient status of injected mice and the continued presence of goat anti-p. combined with the absence of detectable mouse immunoglobulin M in the sera of such p.-suppressed animals (13, 26) . For this reason, we performed gel diffusion analysis on the sera of selected experimental animals either before their use in or at the completion of each experiment to show that they contained goat anti-p. but lacked mouse immunoglobulin M, as described previously (12 
RESULTS
Acute malarial infections in B-cell-deficient mice. Selected characteristics of acute malaria caused by the infection of B-cell-deficient mice with various plasmodia are summarized in Table  1 . Whereas P. yoelii infections were nonlethal in immunologically intact mice, they were uniformly lethal in B-cell-deficient mice of the same strain. Parasitemias became patent at the same time (day 3) and followed similar courses in both types of mice. However, parasitemias in intact mice began to decrease after day 11 postinfection, but continued to increase in B-cell-deficient mice until these animals died.
In contrast, infections with P. vinckei followed the same course in both B-cell-deficient and normal mice. Parasitemias exceeded 60% in both types of mice by day 8 postinfection, and all of the mice died within 24 h thereafter.
A somewhat different pattern of disease was observed when both deficient and intact mice were infected with the lethal parasite P. berghei.
Early on, the kinetics of infection was similar in both types of mice. However, whereas all Bcell-deficient mice had died by day 14, most immunologically intact mice were still alive at this time (Table 1) . By day 25, the remaining animals had died.
Acute infection with P. chabaudi followed similar kinetics in both immunologically intact mice and B-cell-deficient mice. Peak parasitemias occurred 6 to 7 days after infection. None of the infected mice died.
Antibody-independent immunity to recurring malaria in B-cell-deficient mice. When otherwise lethal P. yoelii infections in B-cell-deficient mice were treated with a dosage regimen of clindamycin sufficient to reduce their parasitemias to subpatent levels, the mice subsequently developed chronic low-grade malaria of long-lasting duration, with parasitemias n1l.0%. Such mice were also resistant to exogenous challenge infection with homologous parasites administered 11 weeks after the initiation of acute infection (Table 2). Interestingly, B-cell-deficient mice whose acute P. yoelii infections had seemingly been sterilized by chemotherapy died with fulminating malaria when subsequently challenged with P. yoelii, suggesting that the continued presence of parasites in host tissue was essential to maintain immunity.
To determine the strength of this reinfection immunity in B-cell-deficient mice, animals chronically infected with P. yoelii were injected with enough P. yoelii to yield an immediate patent parasitemia of 0.25%. B-cell-deficient mice which had not been infected with P. yoelii previously, as well as naive immunologically intact mice, received the same inoculum and served as controls. Immtine B-cell-deficient mice cleared the parasites from their blood over a period of several days (Fig. 1) . In contrast, control mice developed typical acute P. yoelii infections which followed predictable courses;
i.e., B-cell-deficient mice developed fulminating malaria and died, whereas naive immunologically intact mice resolved their acute infections.
After the termination of their acute P. chabaudi infections, B-cell-deficient mice, in contrast to immunologically intact mice, developed chronic low-grade malaria. Parasitemias in Bcell-deficient mice ranged between 0.001 and <0.1% for a 3-week period after the resolution of acute malaria (Fig. 2) , at which time the animals were used in a specificity experiment described below. Other experiments showed that chronic P. chabaudi infections persisted for periods of up to 450 days. Such mice were resistant to challenge infection with homologous parasites.
To determine whether B-cell-deficient mice could be protected against reinfection with P. Table 3 show that the ability of Bcell-deficient mice to develop antibody-independent immunity to recurrent malaria was dependent upon both the genotype of the mouse and the infecting species of plasmodia. Whereas a varied but significant portion of B-cell-deficient mice from several mouse strains was immunized by drug-limited P. yoelii infections, none of 25 C57BL/10 mice developed antibody-independent immunity to P. yoelii. In contrast, most Bcell-deficient mice, regardless of genotype, controlled their chronic P. chabaudi parasitemias. As the sex of the animals did not significantly alter the kinetics of these infections (data not shown), results were analyzed without consideration of this factor. However, in any given experiment, groups were matched with respect to age and sex.
Specificity of antibody-independent immunit to malaria in chronically infected B-cell-deficient mice. To determine the specificity of antibodyindependent immunity in B-cell-deficient mice chronically infected with P. yoelii, groups of mice were challenged with heterologous species of plasmodia. Such B-cell-deficient mice immunized against P. yoelii resisted infection with P. chabaudi and P. berghei (Table 4) . Six of seven chronically infected B-cell-deficient mice challenged with heterologous P. vinckei developed full-blown malaria with peak parasitemias of between 27 and 67%. Note, only one of these six B-cell-deficient mice died. The remaining five B- cell-deficient mice immunized against P. yoelii resolved their active P. vinckei challenge infections spontaneously, as did the seventh mouse which had developed low-grade infection upon challenge.
Previously, we had reported that B-cell-deficient mice chronically infected with P. chabaudi were resistant to challenge infection with P. vinckei but were susceptible to infection with either P. berghei or P. yoelii (12) . To determine whether the presence of a chronic P. chabaudi infection in B-cell-deficient mice was capable of influencing the course of a superimposed P. yoelii infection, B-cell-deficient mice with chronic P. chabaudi malaria, as well as naive Bcell-deficient mice, were challenged with P. yoelWi. P. yoelii infections in nonimmune B-celldeficient mice, as well as in B-cell-deficient mice immune to P. chabaudi, were fulminating and lethal (Fig. 2) . The kinetics of the infections was similar regardless of the host's prior experience with P. chabaudi, indicating that mice immune to P. chabaudi were totally lacking immunity to P. yoelii.
Restricted specificity of antibody-independent immunity to challenge infection with heterologous plasmodia was also observed in B-celldeficient mice which had been rescued from otherwise lethal P. vinckei infection by means of chemotherapy with chloroquine. Such immunized mice resisted homologous P. vinckei parasites as well as challenge with P. chabaudi but developed fulminating malaria and died when infected with either P. yoelii or P. berghei (Table  5) . VOL. 41, 1983 on August 14, 2017 by guest http://iai.asm.org/ Clindamycin (75 mg/kg) was administered four times during a 6-day period beginning day 13 after i.v. infection with 105 P. yoelii. Two additional doses of clindamycin were given on days 38 and 42 postinfection. All mice were challenged with 106 pRBC of the designated species 78 days after initiation of the immunizing P. yoelii infection.
DISCUSSION
The investigation described herein represents an extension of previous studies in our laboratory aimed at identifying resistance mechanisms capable of protecting the host against acute malarial infection. In the present study, we have examined immunity to reinfection malaria in Bcell-deficient hosts which had previously experienced acute malaria. Perhaps the most significant finding of the present study was the observation that B-cell-deficient mice which had experienced acute malarial infections caused by different plasmodial species displayed different patterns of resistance to subsequent challenge infections with heterologous species. Thus, Bcell-deficient mice which had been protected by chemotherapy against the lethal effects of acute infection with either P. yoelii or P. vinckei developed acute-type malaria when challenged with the heterologous parasite. Such mice were resistant to homologous challenge infection as well as challenge infection with yet another parasite, P. chabaudi (Table 6 ). In contrast, Bcell-deficient mice immune to P. chabaudi while resistant to P. vinckei remained fully suceptible to P. yoelii. These results indicate that immunity to reinfection malaria in B-cell-deficient mice can be mediated by qualitatively different mechanisms of resistance activated by a particular plasmodial species. Whether challenge infections with P. chabaudi in B-cell-deficient mice with chronic malaria are controlled by identical or different mechanisms of resistance depending upon the plasmodial species used to initiate acute infection remains to be determined. P. chabaudi may prove to be more susceptible than other plasmodia to resistance mechanisms activated by either P. yoelii or P. vinckei.
In addition to being antibody independent, immunity to reinfection malaria in B-cell-deficient hosts requires the participation of T (24) .
Whereas the genetic basis for developing antibody-independent immunity to reinfection malaria awaits future analysis, our results suggest that the genotype of B-cell-deficient mice determines their ability to prevent recurrent malaria. This was most evident in the case of P. yoelii, where significant immunity was induced only in F1 hybrid mice. In contrast, B-cell-deficient mice regardless of genotype readily developed immunity to reinfection with P. chabaudi, indicating that different genetic loci control resistance during chronic malarial infections caused by different species of plasmodia. Other investigators, using different strains of immunologically intact mice, have reported differences in susceptibility to infection with another subspecies of P. chabaudi (9, 21) . Future studies with additional mouse strains made B-cell deficient may reveal similar genotypic differences in susceptibility and provide a basis for defining the antibody-independent mechanisms involved.
Several reports in the literature have suggested that T cells play an essential role in pathological events leading to "early death" in virulent malarial infections (15, 23, 25) . Finley et al. (11) have recently reported that a significant proportion of euthymic mice developed a rapidly fatal neurological syndrome early in the course of infection with P. berghei. In contrast, athymic nude mice failed to demonstrate neurological signs when infected with the same parasite and died late during the course of disease. Whether this was due to a helper role of T cells in the production of antibody capable of mediating pathology or to a direct effector function of a select subset of T lymphocyte has not been determined. The results of the present study show that B-cell-deficient mice infected with either P. vinckei or P. berghei died at the same time or earlier than similarly infected immunologically intact mice. This finding suggests that T cells participate directly as effector cells in producing pathology responsible for causing early death in virulent malarial infections.
In conclusion, these studies represent an ongoing effort to gain insight into mechanisms of resistance induced by infection with hemoprotozoan parasites. Whereas a protective role for antibody has been established in malaria caused by P. falciparum (6, 7) , the identity and significance of other resistance mechanisms responsible for coping with this disease remain purely speculative. However, it is not unlikely that additional mechanisms of resistance do contribute to immunity in the malarious human host. In fact, it has recently been reported (J. Jensen, M. Baland, and M. Akood, Annu. Meet. Am. Soc. Trop. Med. Hyg., 31st, 8 Nov. 1982) that the sera of certain Sudanese living in areas of hyperendemic malaria were inhibitory to the in vitro growth of P. falciparum, despite the absence of antibody activity as measured by immunofluorescence. We hope that the use of immunodeficient animal models in future studies will aid in identifying and characterizing mechanisms of resistance which protect the host against malaria. Although it is recognized that the results of such experiments may not be directly applicable to human malaria, they may provide a basis for VOL. 41, 1983 on August 14, 2017 by guest http://iai.asm.org/ the eventual development of future immunizing agents to be used against this disease.
